Results 231 to 240 of about 126,909 (281)

Cardiac Myosin Inhibitors for Managing Obstructive Hypertrophic Cardiomyopathy: JACC: Heart Failure State-of-the-Art Review.

JACC: Heart Failure, 2023
J. Ostrominski, Ruby Guo, P. Elliott, Carolyn Y. Ho   +3 more
semanticscholar   +2 more sources

Cardiac Myosin Inhibitors: Unlocking Potential to Improve Treatment in Hypertrophic Cardiomyopathy.

Circulation, 2023
A. Turer, Andrew Wang
semanticscholar   +3 more sources

Cardiac Myosin Inhibitors: Is the Emperor Wearing Any Clothes, or Is it Placebo?

Journal of the American College of Cardiology
T. Rasmussen, A. Dybro, M. K. Jensen
semanticscholar   +2 more sources

Two cardiac myosin inhibitors in the treatment of obstructive hypertrophic cardiomyopathy.

Med
A key area of therapeutic progress in obstructive hypertrophic cardiomyopathy revolves around the emergence of cardiac myosin inhibitors, of which mavacamten and aficamten represent the first and second molecules. We summarize the key research evidence, including many similarities and potential differences between various clinical trials studying these
Milind Y. Desai, E. Braunwald
semanticscholar   +3 more sources

The Revolution of Cardiac Myosin Inhibitors in Hypertrophic Cardiomyopathy.

Canadian Journal of Cardiology
Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiomyopathy worldwide and causes significant morbidity and mortality. For decades, medical treatment options have been limited and untargeted, with frequent need for invasive interventions not readily accessible to many HCM patients.
Rebecca Haraf, Hany Habib, A. Masri
semanticscholar   +3 more sources

Mavacamten, a First-in-Class Cardiac Myosin Inhibitor for Obstructive Hypertrophic Cardiomyopathy

Annals of Pharmacotherapy, 2022
Objective: To assess mavacamten’s role in hypertrophic cardiomyopathy treatment. Data Sources: In addition to clinical guidelines, package inserts, and general reviews, we searched PubMed using the term mavacamten from inception to June 11, 2022. Study Selection and Data Extraction: English language studies describing mavacamten’s mechanism of action ...
Joseph D. Dalo, Nissen D. Weisman, C. Michael White   +2 more
openaire   +2 more sources

Abstract 15493: The Efficacy of Cardiac Myosin Inhibitors versus Placebo in Patients With Symptomatic Hypertrophic Cardiomyopathy

Circulation, 2022
The Efficacy of Cardiac Myosin Inhibitors Versus Placebo in Patients with Symptomatic Hypertrophic Cardiomyopathy. Introduction: Given the interplay between hypertrophic cardiomyopathy, elevated resting LVOT gradients (≥ 50 mm Hg) and heart ...
Mohammad Yassen, C. Burmeister, Khalid Changal   +2 more
semanticscholar   +1 more source

Selective cardiac myosin inhibitors protect the heart following ischemia-reperfusion injury

European Heart Journal, 2023
Abstract Background/Introduction Following an acute myocardial infarction, reperfusion of an occluded coronary artery is often accompanied by cardiomyocyte injury, leading to a worse long-term prognosis.
L Yusof, D M Yellon, S M Davidson
openaire   +1 more source

Effects of Sarcomere Activators and Inhibitors Targeting Myosin Cross-Bridges on Ca2+-Activation of Mature and Immature Mouse Cardiac Myofilaments

Molecular Pharmacology, 2022
We tested the hypothesis that isoform shifts in sarcomeres of the immature heart modify the effect of cardiac myosin-directed sarcomere inhibitors and activators.
M. Halas, Paulina Langa, C. Warren, P. Goldspink, B. Wolska, R., J. Solaro   +6 more
semanticscholar   +1 more source

First-in-class cardiac myosin inhibitor reduces symptoms of HCM

Nature Reviews Cardiology, 2020
Mavacamten, a first-in-class cardiac myosin inhibitor, reduces symptoms and improves health status in patients with obstructive hypertrophic cardiomyopathy, according to findings from the EXPLORER-HCM trial.
openaire   +2 more sources